http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107531721-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4162
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4162
filingDate 2016-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e31df0ddae2f34255463005016b0c00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_061f5c239ce658b194c041aa5d8efb38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afef67a927e677070972aaf73e0afc82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e172f775bf7c1a54ba407a695ece9ed3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db8bb1281fcbbf54a25efde22acef76d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf1d510a675a299ac420f12d76d80597
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8145392922590ec97d3103d7a9aae58
publicationDate 2018-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-107531721-A
titleOfInvention Fused tricyclic pyrazole derivatives for modulating farnesoid X receptors
abstract The present invention relates to compounds of formula I, Stereoisomers, enantiomers, pharmaceutically acceptable salts or amino acid conjugates thereof; wherein the variables are as defined herein; and the invention also relates to pharmaceutical compositions thereof for use as farnesol X receptors modulator of FXR activity.
priorityDate 2015-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015069666-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010049366-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105682656-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101448791-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468090751
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID430527021
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465803595
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466316055
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID164008380
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468184687
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID122663072
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468095926

Total number of triples: 42.